STUDY TO ASSESS THE BENEFITS OF MILRINONE IN PREVENTION OF COMPLICATIONS ASSOCIATED WITH ARTERIAL CONSTRICTION IN PATIENTS WHO HAVE SEVERE SUBARACHNOID HEMORRHAGE DUE TO RUPTURED INTRACRANIAL ANEURYSM

Effectiveness of low intravenous infusion of milrinone in prevention of cerebral vasospasm following endovascular management of aneurysmal subarachnoid hemorrhage. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/083160

Enrollment

Registered

2025-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I607- Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery

Interventions

Intervention1: Group A - milrinone group: Prophylactic low dose intravenous milrinone infusion in adjunct to the routine prophylactic therapy (hydration, euvolemic hypertension) and oral nimodipine th

Eligibility

Inclusion criteria

Inclusion criteria: 1) Willing to give consent for participating in the study. 2) Pre-procedure high grade (3 or 4) mFS SAH 3) undergoing endovascular treatment

Exclusion criteria

Exclusion criteria: 1) Patients unwilling to participate in the study / not giving consent. 2) Patients not willing to be followed up. 3) Patients with cardiac disease, 4) Patients with hypokalemia 5) Patients with severe renal dysfunction. 6) patients with non aneurysmal SAH 7) Patients who have already developed NCCT evidence of infarction/hydrocephalus before day 3 of ictus.

Design outcomes

Primary

Measure	Time frame
assess the role of low dose intravenous infusion of milrinone in patients with high grade aSAH post endovascular intervention to prevent development of cerebral vasospasm. To assess the efficacy of intravenous milrinone in prevention of development of clinically significant vasospasm. following parameters will be assessed: 1)Incidence of development of clinically significant vasospasm during the hospital stay. 2)Requirement of intra-arterial nimodipine rescue therapy 3)Number of sessions of intra-arterial nimodipine rescue therapy required 4) Morbidity or mortality associated with the episode of vasospasm.Timepoint: Daily during hospital stay from day 04 till day 11 of ictus	—

Measure

Time frame

assess the role of low dose intravenous infusion of milrinone in patients with high grade aSAH post endovascular intervention to prevent development of cerebral vasospasm. To assess the efficacy of intravenous milrinone in prevention of development of clinically significant vasospasm. following parameters will be assessed: 1)Incidence of development of clinically significant vasospasm during the hospital stay. 2)Requirement of intra-arterial nimodipine rescue therapy 3)Number of sessions of intra-arterial nimodipine rescue therapy required 4) Morbidity or mortality associated with the episode of vasospasm.Timepoint: Daily during hospital stay from day 04 till day 11 of ictus

—

Secondary

Measure	Time frame
long term outcomes of prophylactic low dose intravenous milrinone therapy and its effectiveness in preventing disability assessed by modified Rankin scale (mRS)Timepoint: 6 weeks and 3 months after ictus.	—

Countries

India

Contacts

Public ContactAjay Kumar

Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh

navojitchatterjee93@gmail.com9910341396

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026